Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats

Journal of Neuroinflammation

Nai Hong Chen³  Hua Li²  Zhen Zhen Wang³  Xiao Mei Zhuang²  Ning Han³  Zhi Yuan Wang¹  Ling Lei Kong³ 

[1] The Lab of Biopharmaceutics, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China;The Key Lab of Drug Metabolism and Pharmacokinetics, Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Haidian District, Beijing 100850, China;State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xiannongtan Street, Xuanwu District, Beijing 100050, China

关键词: Mitogen-activated protein kinase;    Neutrophil infiltration;    Adhesion molecular;    Inflammation;    Cerebral ischemia;    Chemokine-like factor 1;   

Others  :  803446
DOI  :  10.1186/1742-2094-11-112

 received in 2014-02-03, accepted in 2014-06-06,  发布年份 2014

【 摘 要 】

Background

Inflammation plays a key role in the pathophysiology of ischemic stroke. Some proinflammatory mediators, such as cytokines and chemokines, are produced in stroke. Chemokine-like factor 1 (CKLF1), as a novel C-C chemokine, displays chemotactic activities in a wide spectrum of leukocytes and plays an important role in brain development. In previous studies, we have found that the expression of CKLF1 increased in rats after focal cerebral ischemia and treatment with the CKLF1 antagonist C19 peptide decreased the infarct size and water content. However, the role of CKLF1 in stroke is still unclear. The objective of the present study was to ascertain the possible roles and mechanism of CKLF1 in ischemic brain injury by applying anti-CKLF1 antibody.

Methods

Male Sprague–Dawley rats were subjected to one-hour middle cerebral artery occlusion. Antibody to CKLF1 was applied to the right cerebral ventricle immediately after reperfusion; infarct volume and neurological score were measured at 24 and 72 hours after cerebral ischemia. RT-PCR, Western blotting and ELISA were utilized to characterize the expression of adhesion molecules, inflammatory factors and MAPK signal pathways. Immunohistochemical staining and myeloperoxidase activity was used to determine the extent of neutrophil infiltration.

Results

Treatment with anti-CKLF1 antibody significantly decreased neurological score and infarct volume in a dose-dependent manner at 24 and 72 hours after cerebral ischemia. Administration with anti-CKLF1 antibody lowered the level of inflammatory factors TNF-α, IL-1β, MIP-2 and IL-8, the expression of adhesion molecules ICAM-1 and VCAM-1 in a dose-dependent manner. The results of immunohistochemical staining and detection of MPO activity indicated that anti-CKLF1 antibody inhibited neutrophil infiltration. Further studies suggested MAPK pathways associated with neutrophil infiltration in cerebral ischemia.

Conclusions

Selective inhibition of CKLF1 activity significantly protects against ischemia/reperfusion injury by decreasing production of inflammatory mediators and expression of adhesion molecules, thereby reducing neutrophils recruitment to the ischemic area, possibly via inhibiting MAPK pathways. Therefore, CKLF1 may be a novel target for the treatment of stroke.

【 授权许可】

   
2014 Kong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Muir KW, Tyrrell P, Sattar N, Warburton E: Inflammation and ischaemic stroke. CurrOpinNeurol 2007, 20:334-342.
• [2]Wang Q, Tang XN, Yenari MA: The inflammatory response in stroke. J Neuroimmunol 2006, 184:53-68.
• [3]Jaerve A, Müller HW: Chemokines in CNS injury and repair. Cell Tissue Res 2012, 349:229-248.
• [4]Banisadr G, Rostène W, Kitabgi P, Parsadaniantz SM: Chemokines and brain functions. Curr Drug Targets Inflamm Allergy 2005, 4:387-399.
• [5]Rostene W, Buckingham JC: Chemokines as modulators of neuroendocrine functions. J MolEndocrinol 2007, 38:351-353.
• [6]Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
• [7]Losy J, Zaremba J: Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke 2001, 32:2695-2696.
• [8]Che X, Ye W, Panga L, Wu DC, Yang GY: Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res 2001, 902:171-177.
• [9]Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q, Zhao R, Di CH, Song QS, Ma DL: Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci 2006, 78:614-621.
• [10]Li T, Zhong J, Chen Y, Qiu X, Zhang T, Ma DL, Han WL: Expression of chemokine-like factor 1 is upregulated during T lymphocyte activation. Life Sci 2006, 79:519-524.
• [11]Wang ZZ, Li G, Chen XY, Zhao M, Yuan YH, Wang XL, Chen NH: Chemokine-like factor 1, a novel cytokine, induces nerve cell migration through the non-extracellular Ca2+-dependent tyrosine kinases pathway. Brain Res 2010, 1308:24-34.
• [12]Wang ZZ, Zhang Y, Yuan YH, Chen NH: Developmental expression of chemokine-like factor 1, a novel member of chemokines family, in postnatal rat cerebral cortex. NeurosciLett 2012, 519:51-55.
• [13]Kong LL, Hu JF, Zhang W, Yuan YH, Ma KL, Han N, Chen NH: Expression of chemokine-like factor 1 after focal cerebral ischemia in the rat. NeurosciLett 2011, 505:14-18.
• [14]Kong LL, Hu JF, Zhang W, Yuan YH, Han N, Chen NH: C19, a C-terminal peptide of chemokine-like factor 1, protects the brain against focal brain ischemia in rats. NeurosciLett 2012, 508:13-16.
• [15]Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
• [16]Liu S, Zhen G, Meloni BP, Campbell K, Winn HR: Rodent stroke model guidelines for preclinical stroke trials (1st edition). J Exp Stroke Transl Med 2009, 2:2-27.
• [17]Maddahi A, Ansar S, Chen Q, Edvinsson L: Blockade of the MEK/ERK pathway with a raf inhibitor prevents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow after subarachnoid hemorrhage in a rat model. J Cereb Blood Flow Metab 2011, 31:144-154.
• [18]Kaminska B: MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. BiochimBiophysActa 2005, 1754:253-262.
• [19]Benakis C, Bonny C, Hirt L: JNK inhibition and inflammation after cerebral ischemia. Brain BehavImmun 2010, 24:800-811.
• [20]Nijboer CH, Bonestroo HJ, Zijlstra J, Kavelaars A, Heijnen CJ: Mitochondrial JNK phosphorylation as a novel therapeutic target to inhibit neuroinflammation and apoptosis after neonatal ischemic brain damage. Neurobiol Dis 2013, 54:432-444.
• [21]Ahmad M, Graham SH: Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res 2010, 1:74-84.
• [22]Schuette-Nuetgen K, Strecker JK, Minnerup J, Ringelstein EB, Schilling M: MCP-1/CCR-2-double-deficiency severely impairs the migration of hematogenous inflammatory cells following transient cerebral ischemia in mice. ExpNeurol 2012, 233:849-858.
• [23]Sousa LF, Coelho FM, Rodrigues DH, Campos AC, BarcelosLda S, Teixeira MM, Rachid MA, Teixeira AL: Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics 2013, 68:391-394.
• [24]Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV: Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 2007, 38:1345-1353.
• [25]Hughes PM, Allegrini PR, Rudin M, Perry VH, Mir AK, Wiessner C: Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab 2002, 22:308-317.
• [26]Huang J, Li Y, Tang Y, Tang G, Yang GY, Wang Y: CXCR4 antagonist AMD3100 protects blood brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke 2013, 44:190-197.
• [27]Lambertsen KL, Biber K, Finsen B: Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 2012, 32:1677-1698.
• [28]Tan YX, Han WL, Chen YY, Ouyang NT, Tang Y, Li F, Ding PG, Ren XL, Zeng GQ, Ding J, Zhu T, Ma DL, Zhong NS: Chemokine-like factor 1, a novel cytokine, contributes to airway damage, remodeling and pulmonary fibrosis, artery occlusion model. Chin Med J (Engl) 2004, 117:1123-1129.
• [29]Wang Y, Zhang Y, Han W, Li D, Tian L, Yin C, Ma D: Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4. Int J Biochem Cell Biol 2008, 40:909-919.
• [30]Tian L, Li W, Wang J, Zhang Y, Zheng Y, Qi H, Guo X, Zhang Y, Ma D, Shen H, Wang Y: The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma. Allergy 2011, 66:287-297.
• [31]Jin R, Yang G, Li G: Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J LeukocBiol 2010, 87:779-789.
• [32]Brea D, Sobrino T, Ramos-Cabrer P, Castillo J: Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia. Cerebrovasc Dis 2009, 27:48-64.
• [33]Abbott NJ: Inflammatory mediators and modulation of blood–brain barrier permeability. Cell MolNeurobiol 2000, 20:131-147.
• [34]Lambertsen KL, Biber K, Finsen B: Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 2012, 9:1677-1698.
• [35]Huang J, Upadhyay UM, Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. SurgNeurol 2006, 66:232-245.
• [36]Becker K, Kindrick D, Relton J, Harlan J, Winn R: Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke 2001, 32:206-211.
• [37]Kanemoto Y, Nakase H, Akita N, Sakaki T: Effects of anti-intercellular adhesion molecule-1 antibody on reperfusion injury induced by late reperfusion in the rat middle cerebral artery occlusion model. Neurosurgery 2002, 51:1034-1041.
• [38]Liesz A, Zhou W, Mracskó É, Karcher S, Bauer H, Schwarting S, Sun L, Bruder D, Stegemann S, Cerwenka A, Sommer C, Dalpke AH, Veltkamp R: Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 2011, 134:704-720.
• [39]Ma XJ, Cheng JW, Zhang J, Liu AJ, Liu W, Guo W, Shen FM, Lu GC: E-selection deficiency attenuates brain ischemia in mice. CNS NeurosciTher 2012, 18:903-908.
• [40]Shichita T, Sakaguchi R, Suzuki M, Yoshimura A: Post-ischemic inflammation in the brain. Front Immunol 2012, 3:132.
• [41]Lucas SM, Rothwell NJ, Gibson RM: The role of inflammation in CNS injury and disease. Br J Pharmacol 2006, 147:S232-S240.
• [42]Fernández-López D, Vexler ZS: Blood–brain barrier and stroke. Top Med Chem 2013, 23:1-26.
• [43]Nozaki K, Nishimura M, Hashimoto N: Mitogen-activated protein kinases and cerebral ischemia. MolNeurobiol 2001, 23:1-19.
• [44]Kovalska M, Kovalska L, Pavlikova M, Janickova M, Mikuskova K, Adamkov M, Kaplan P, Tatarkova Z, Lehotsky J: Intracellular signaling MAPK pathway after cerebral ischemia-reperfusion injury. Neurochem Res 2012, 7:1568-1577.
• [45]Wang H, Xu L, Venkatachalam S, Trzaskos JM, Friedman SM, Feuerstein GZ, Wang X: Differential regulation of IL-1beta and TNF-alpha RNA expression by MEK1 inhibitor after focal cerebral ischemia in mice. BiochemBiophys Res Commun 2001, 286:869-874.
• [46]Maddahi A, Edvinsson L: Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway. J Neuroinflammation 2010, 7:14.
• [47]Guo RB, Wang GF, Zhao AP, Gu J, Sun XL, Hu G: Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-κB-mediated inflammatory responses. PLoS One 2012, 11:e49701.
• [48]Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA: Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev 2001, 21:129-145.
• [49]Wang ZQ, Wu DC, Huang FP, Yang GY: Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Res 2004, 996:55-66.